Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis

Annals of Internal Medicine

Volumn 113, Issue 9, 1990, Pages 656-663

  Falk, Ronald J ^a,b   Hogan, Susan ^a,b   Carey, Timothy S ^a   Jennette, J Charles ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Div of Nephrology and Hypertension   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GRANULOCYTE ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; DRUG COMBINATION; DRUG EFFICACY; GLOMERULONEPHRITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POLYARTERITIS NODOSA; PRIORITY JOURNAL; SURVIVAL; VASCULITIS; WEGENER GRANULOMATOSIS;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTOPLASM; FEMALE; GLOMERULONEPHRITIS; HUMAN; MALE; MIDDLE AGE; NEUTROPHILS; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; VASCULITIS;

EID: 0025130164     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-113-9-656     Document Type: Article

References (31)

1. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988;318:1651-7.
2. Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Palhol. 1989;135:921-30.
3. Jennette JC, Falk RJ. Anti-neutrophil cytoplasmic autoantibodies and associated diseases: a review. Am J Kidney Dis. 1990;15:517-29.
4. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies in the classification of glomerulonephritis and vasculitis. Kidney Int. 1990;[In press].
5. Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J. 1982;285:606.
6. Hall JB, Wadbam BM, Wood CJ, Ashton V, Adam WR. Vasculitis and glomerulonephritis: a subgroup with an antineutrophil cytoplasmic antibody. Aust N Z J Med. 1984;14:277-8.
7. van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985;1:425-9.
8. Gross WL, Ludemann J, Kiefer G, Lehmann H. Anticytoplasmic antibodies in Wegener's granulomatosis. Lancet. 1986;1:806.
9. Ludemann J, Gross WL. Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis. Clin Exp Immunol. 1987;69:350-7.
10. Savage CO, Winearls CG, Jones S, Marshall PD, Lockwood CM. Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet. 1987; 1:1389-93.
11. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Null Acad Sci USA. 1990;87: 4115-9.
12. Charles LA, Falk RJ, Jennette JC. Reactivity of anti-neutrophil cytoplasmic autoantibodies with HL-60 cells. Clin Immunol Immunopathol. 1989;53:243-53.
13. Ludemann J, Utecht B, Gross WL. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme. J Exp Med. 1990;171:357-62.
14. Goldschmeding R, van der School CE, ten Bokkel Huinink D, et al. Wegener's granulomatosis autoantibodies identify a novel dilsopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest. 1989;84:1577-87.
15. Niles JL, McCluskey RT, Ahmad MF, Arnaout MA. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood. 1989;74:1888-93.
16. Jennette JC, Hoidal JH, Falk RJ. Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. Blood. 1990;78:2263-4.
17. Cohen Tervaert JW, Goldschmeding R, Elema JD, et al. Autoantibodies against myelolysosomal enzymes in crescentic glomerulonephritis. Kidney Int. 1990;37:799-806.
18. Cox DR. Regression models and life tables (with discussion). J Roy Statist Soc Ser B. 1972;34:187-220.
19. SAS Institute, Inc. The PHGLM Procedure. SAS Sugi Supplemental Library User's Guide. 1986;5:437-66.
20. Jennette JC, Wall SD, Wilkman AS. Low incidence of IgA nephropathy in blacks. Kidney Int. 28:944-50.
21. Godman GC, Churg J. Wegener's granulomatosis. Pathology and review of the literature. Arch Pathol. 1954;58:533-53.
22. Yoshikawa Y, Watanabe T. Pulmonary lesions in Wegener's granulomatosis: a clinicopathologic study of 22 autopsy cases. Hum Pathol. 1986;17:401-10.
23. Fauci AS, Haynes BF, Katz P. The spectrum of vasculitis. Clinical, pathologic, immunologic, and therapeutic considerations. Ann Intern Med. 1978;89:660-76.
24. Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis. 1988;11: 449-64.
25. Savage CO, Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteris: presentation, pathology, prognosis. Q J Med. 1985;220:467-83.
26. Fuiano G, Cameron JS, Raftry M, Hartley BH, Williams DG, Ogg CS. Improved prognosis of renal polyarteritis in recent years. Nephrol Dial Transplant. 1988;3:383-91.
27. Leib BS, Restivo C, Paulus HE. Immunosuppressive therapy and corticosteroid therapy of polyarteritis nodosa. Am J Med. 1979;67: 941-7.
28. Balow JE. Renal vasculitis. Kidney Int. 1985;27:954-64.
29. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98:76-85.
30. Nolle B, Specks U, Ludemann J, Rohrbach MS, DeRemee RA, Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med. 1989;111:28-40.
31. Cohen Tervaert JW, van der Woude FJ, Fauci AS, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med. 1989;149:2461-5.